Nektar Therapeutics (NKTR) News Today $0.76 -0.04 (-5.46%) Closing price 04:00 PM EasternExtended Trading$0.77 +0.01 (+1.87%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)March 26 at 11:33 PM | markets.businessinsider.comNektar management to meet with Piper SandlerMarch 24 at 6:39 PM | markets.businessinsider.comNektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market TurmoilMarch 22, 2025 | insidermonkey.comPrimecap Management Co. CA Decreases Position in Nektar Therapeutics (NASDAQ:NKTR)Primecap Management Co. CA lowered its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,540,386 shares of the biopharmaceuMarch 21, 2025 | marketbeat.comNektar Therapeutics to Participate in the H.C. ...March 20, 2025 | gurufocus.comNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | prnewswire.comHC Wainwright Has Optimistic Outlook of NKTR Q1 EarningsMarch 18, 2025 | americanbankingnews.comHC Wainwright Issues Positive Estimate for NKTR EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst A. He now anticipates that the biopharmaMarch 17, 2025 | marketbeat.comQ1 EPS Estimate for Nektar Therapeutics Boosted by AnalystNektar Therapeutics (NASDAQ:NKTR - Free Report) - William Blair lifted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research report issued on Thursday, March 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.19March 17, 2025 | marketbeat.comOppenheimer Upgrades Nektar Therapeutics (NKTR)March 15, 2025 | msn.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by OppenheimerOppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a report on Friday.March 15, 2025 | marketbeat.comWilliam Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)March 14, 2025 | markets.businessinsider.comNektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 14, 2025 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comWilliam Blair Reiterates Market Perform Rating for Nektar Therapeutics (NASDAQ:NKTR)William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Thursday.March 14, 2025 | marketbeat.comQ4 2024 Nektar Therapeutics Earnings CallMarch 13, 2025 | uk.finance.yahoo.comNektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in JuneMarch 13, 2025 | markets.businessinsider.comNektar up 12% to 91c after Oppenheimer upgrade with $6 targetMarch 13, 2025 | markets.businessinsider.comNektar Therapeutics (NASDAQ:NKTR) Releases Earnings Results, Beats Expectations By $0.33 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.March 13, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Posts Quarterly Earnings Results, Beats Estimates By $0.33 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.March 13, 2025 | marketbeat.comNektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market PotentialMarch 13, 2025 | tipranks.comNektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...March 13, 2025 | gurufocus.comQ4 2024 Nektar Therapeutics Earnings Call TranscriptMarch 13, 2025 | gurufocus.comNektar reports Q4 adjusted EPS (15c), consensus (19c)March 12, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Q4 Earnings Beat EstimatesMarch 12, 2025 | msn.comNektar Therapeutics (NKTR) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 12, 2025 | prnewswire.comNektar Therapeutics Q4 2024 Earnings PreviewMarch 11, 2025 | msn.comNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial MarketsMarch 5, 2025 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy ratinMarch 5, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Lemaitre Vascular (LMAT), Catalyst Pharma (CPRX) and Nektar Therapeutics (NKTR)February 28, 2025 | markets.businessinsider.comNektar completes enrollment in REZOLVE-AA Phase 2b trial of rezpegaldesleukinFebruary 26, 2025 | markets.businessinsider.comNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia AreataFebruary 26, 2025 | prnewswire.comWilliam Blair Reaffirms "Market Perform" Rating for Nektar Therapeutics (NASDAQ:NKTR)William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comBTIG Remains a Buy on Nektar Therapeutics (NKTR)February 25, 2025 | markets.businessinsider.comNektar Therapeutics (NASDAQ:NKTR) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $6.50 target price on shares of Nektar Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comBuy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 DiabetesFebruary 25, 2025 | tipranks.comWilliam Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)February 25, 2025 | markets.businessinsider.comNektar Therapeutics: Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes MellitusFebruary 24, 2025 | finanznachrichten.deNektar announces clinical trial agreement to evaluate RezpegaldesleukinFebruary 24, 2025 | markets.businessinsider.comNektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24thFebruary 24, 2025 | prnewswire.comNektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes MellitusFebruary 24, 2025 | prnewswire.comNektar Therapeutics (NKTR) to Release Earnings on MondayNektar Therapeutics (NASDAQ:NKTR) will be releasing earnings before the market opens on Monday, March 3.February 24, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 SharesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 10,300 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total transaction of $10,403.00. Following the transaction, the insider now owns 316,604 shares in the company, valued at approximately $319,770.04. This represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.February 23, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 SharesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 10,300 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total value of $10,403.00. Following the completion of the sale, the insider now directly owns 316,604 shares in the company, valued at $319,770.04. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 22, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $24,011.74 in StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard W. Robin sold 23,774 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total transaction of $24,011.74. Following the completion of the transaction, the chief executive officer now directly owns 1,086,901 shares in the company, valued at approximately $1,097,770.01. The trade was a 2.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.February 22, 2025 | marketbeat.comNektar Therapeutics chief legal officer sells shares worth $11,150February 21, 2025 | investing.comNektar Therapeutics officer sells shares worth over $10,000February 21, 2025 | investing.comB.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)February 17, 2025 | markets.businessinsider.com Remove Ads Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.540.78▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼73▲NKTR Articles Average Week Remove Ads Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NKTR Stock Free NKTR Stock Alerts